Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Summary

The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments. No reparative therapies exist for the treatment of multiple sclerosis. Clemastine fumarate was identified along with a series of other antimuscarinic medications as a potential remyelinating agent using the micropillar screen (BIMA) developed at the University of California, San Francisco (UCSF).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Multiple Sclerosis (MS)
• Multiple Sclerosis, Relapsing-Remitting
• Multiple Sclerosis, Primary Progressive
• Multiple Sclerosis, Chronic Progressive
• Multiple Sclerosis Relapse
• Multiple Sclerosis Brain Lesion
• Multiple Sclerosis Benign

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 55 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

University of California, San Francisco

Last updated on ClinicalTrials.gov

July 2, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites